PIM1 and hepatoblastoma: These findings highlight the premise of PIM inhibition as an adjunct for the treatment of cisplatin-insensitive hepatoblastoma, by targeting the chemoresistant SCLCC population and significantly reducing the SCLCC frequency which, along with the decreased proliferation and increased cisplatin-induced apoptosis of the non-SCLCC population, could ideally lead to an improved or renewed response to cisplatin.